Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Expands By 20.3%

SOPHiA GENETICS SA (NASDAQ:SOPH) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 254,959 shares, an increase of 20.3% from the March 15th total of 211,974 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average daily trading volume, of 96,355 shares, the days-to-cover ratio is currently 2.6 days.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Strategic commercial win — Mount Sinai Health System will adopt SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform to support precision cancer care and genomic testing at an NCI-designated center, a high-visibility customer that could drive recurring software usage and credibility in the U.S. market. Mount Sinai collaboration
• Positive Sentiment: Sector reinforcement — coverage of Mount Sinai using AI to speed genomic testing underscores demand for AI-driven genomics platforms, supporting the case for broader SOPHiA DDM adoption and long-term revenue potential. Healthcare IT News
• Positive Sentiment: Analyst backing — recent analyst notes have raised price targets and issued buy ratings (e.g., BTIG, Guggenheim), giving investors a visible upside reference versus current levels and likely contributing to bullish sentiment.
• Neutral Sentiment: Insider selling disclosed — multiple insiders (CEO, President and others) sold tens of thousands of shares in mid‑April under pre‑arranged Rule 10b5‑1 plans, largely to cover tax withholding on vested awards. These are scheduled/tax-related sales (increasing float but not necessarily signaling negative inside-view). SEC Form 4 (example)
• Negative Sentiment: Profitability concerns persist — SOPH reported a March-quarter EPS miss (reported ($0.28) vs. consensus ($0.20)), negative margins and a large negative ROE; analysts still expect FY losses (~-0.96 EPS), which can cap valuation expansion despite commercial progress. Earnings & metrics

Wall Street Analyst Weigh In

Several brokerages have recently commented on SOPH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Guggenheim raised their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, BTIG Research raised their price objective on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, SOPHiA GENETICS presently has a consensus rating of “Hold” and a consensus price target of $7.50.

SOPHiA GENETICS Stock Performance

Shares of SOPH stock opened at $5.28 on Friday. The company has a market cap of $361.63 million, a price-to-earnings ratio of -10.35 and a beta of 1.04. SOPHiA GENETICS has a 52 week low of $2.58 and a 52 week high of $5.70. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The firm has a 50 day moving average of $4.76 and a 200-day moving average of $4.73.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The business had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. On average, equities analysts forecast that SOPHiA GENETICS will post -0.96 earnings per share for the current year.

Insider Activity at SOPHiA GENETICS

In other news, CEO Jurgi Camblong sold 17,473 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $5.00, for a total transaction of $87,365.00. Following the completion of the sale, the chief executive officer owned 3,646,967 shares of the company’s stock, valued at $18,234,835. This trade represents a 0.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 181,300 shares of company stock worth $880,323. Company insiders own 4.88% of the company’s stock.

Institutional Trading of SOPHiA GENETICS

Several hedge funds have recently bought and sold shares of SOPH. Savvy Advisors Inc. acquired a new stake in SOPHiA GENETICS in the 3rd quarter valued at $48,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS in the 3rd quarter valued at $49,000. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the 4th quarter valued at $49,000. Quadrature Capital Ltd acquired a new stake in SOPHiA GENETICS in the 4th quarter valued at $54,000. Finally, XTX Topco Ltd acquired a new stake in SOPHiA GENETICS in the 4th quarter valued at $55,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.